MorningMed is a community of 814,300 medical professionals

We're a place where medical professionals share news and other news items to help their peers stay up to date

All articles tagged: Delta-beta thalassemia (D56.2)

Evalytics 22 January at 02.18 PM

FDA clears first CRISPR treatment for a second disease, beta thalassemia

The FDA has approved Casgevy, a CRISPR-based medicine, for treating beta thalassemia, a serious blood disorder. This innovative treatment, also used for sickle cell disease, modifies stem cells to boost hemoglobin production, offering a new option for patients.

HealthDay 17 January at 05.10 PM

FDA Approves Casgevy to Treat Beta-Thalassemia

After approving Casgevy (exagamglogene autotemcel) in December to treat sickle cell disease, the U.S. Food and Drug Administration announced Tuesday that the therapy has now been approved to treat patients older than 12 years with transfusion-dependent beta-thalassemia.Casgevy is the first CRIS